Skip to main content
. 2019 Dec 11;9(12):366. doi: 10.3390/brainsci9120366

Table 2.

Comparisons between the cytokine levels in GI vs. No-GI groups, in EO ASD (a) vs. Reg-DD (b) vs. Reg+DD (c) subgroups and No-Verbal vs. Verbal groups. The mean levels of each cytokine in the total sample are also reported.

a b c
Total Sample No-GI
55 Subjects
GI
30 Subjects
p
(No-GI vs. GI)
EO ASD Reg − DD Reg + DD ANOVA
p Value
NO
VERBAL
46 Subjects
VERBAL
39 Subjects
p
(No-V vs. V)
N (%) 85
(100)
55 (64.7%) 30 (35.3%) 57
(67.0)
14
(16.5)
14
(16.5)
TNF-α,
m (SD) pg/mL
range 0.74–16.09
6.12
(2.40)
5.84 (2.01) 6.63 (2.95) ns 6.09 (3.16) 6.76 (3.16) 5.56 (2.56) ns 6.52
(2.57)
5.63
(2.50)
ns
IL-6,
m (SD) pg/mL
range 0.80–104.00
5.99
(16.17)
4.70 (13.83) 8.34 (19.80) ns 5.74 (14.47) 10.82 (27.24) 2.18 (0.90) ns 4.67
(6.96)
7.54
(22.69)
ns
CCL2,
m (SD) pg/mL
range 26.36–451.00
127.22
(58.81)
131.61 (66.86) 119.16 (39.90) ns 126.85 (56.03) 135.10 (53.15) 120.84 (76.74) ns 125.38
(53.73)
129.39
(64.95)
ns
Leptin,
m (SD) pg/mL
range 0.03–4.83
1.14
(0.89)
1.19 (0.96) 1.06 (0.76) ns 1.26 (1.01) 0.96 (0.50) 0.88 (0.55) ns 1.01
(0.80)
1.30
(0.97)
ns
Resistin,
m (SD) ng/mL
range 8.1–96.8
22.89
(13.63)
24.50 (14.37) 19.82 (11.74) 0.032 20.97 (10.45) 18.30 (9.68) 35.14 (20.75) 0.0003 (c > a)
0.0007 (c > b)
23.65
(15.78)
21.96
(10.60)
ns
PAI-1,
m (SD) ng/mL
range 5.5–91.2
26.04
(18.96)
27.52 (20.27) 23.24 (16.13) ns 23.28 (12.74) 22.46 (14.04) 40.67 (33.68) 0.0018 (c > a)
0.0090 (c > b)
28.66
(22.86)
22.88
(12.32)
ns

ns: not significant; Abbreviations (in alphabetic order): ASD: Autism Spectrum Disorder; CCL2: Macrophage Chemoattractant Protein-1; EO ASD: early onset of ASD without a history of loss of competences; GI: gastrointestinal; IL-6: interleukin-6; PAI 1: Plasminogen Activator Inhibitor-1; Reg – DD: regression without a previous developmental delay; Reg + DD: regression with a previous developmental delay; SD: standard deviation; TNF-α: Tumor Necrosis Factor-alpha.